NYMC Faculty Publications


Efficacy, Safety Profile, and Immunogenicity of Alglucosidase Alfa Produced at the 4,000-Liter Scale in US Children and Adolescents with Pompe Disease: ADVANCE, A Phase IV, Open-Label, Prospective Study

First Page


Last Page


Document Type


Publication Date

January 2018




Purpose: Pompe disease results from lysosomal acid alpha-glucosidase (GAA) deficiency and its associated glycogen accumulation and muscle damage. Alglucosidase alfa (recombinant human GAA (rhGAA)) received approval in 2006 as a treatment for Pompe disease at the 160 L production scale. In 2010, larger-scale rhGAA was approved for patients up to 8 years old without cardiomyopathy. NCT01526785 evaluated 4,000 L rhGAA efficacy/safety in US infantile- or late-onset Pompe disease (IOPD, LOPD) patients up to 1 year old transitioned from 160 L rhGAA.MethodsA total of 113 patients (87 with IOPD; 26 with LOPD) received 4,000 L rhGAA for 52 weeks dosed the same as previous 160 L rhGAA. Efficacy was calculated as the percentage of patients stable/improved at week 52 (without death, new requirement for invasive ventilation, left ventricular mass z-score increase >1 if baseline was >2, upright forced vital capacity decrease >/=15% predicted, or Gross Motor Function Measure-88 decrease >/=8 percentage points). Safety evaluation included an extension


Please see the work itself for the complete list of authors.